98%
921
2 minutes
20
Aims: In patients with acute myocardial infarction (MI) and multivessel coronary artery disease, percutaneous coronary intervention (PCI) of non-infarct-related artery reduces death or MI. However, whether selective PCI guided by fractional flow reserve (FFR) is superior to routine PCI guided by angiography alone is unclear. The current trial sought to compare FFR-guided PCI with angiography-guided PCI for non-infarct-related artery lesions among patients with acute MI and multivessel disease.
Methods And Results: Patients with acute MI and multivessel coronary artery disease who had undergone successful PCI of the infarct-related artery were randomly assigned to either FFR-guided PCI (FFR ≤0.80) or angiography-guided PCI (diameter stenosis of >50%) for non-infarct-related artery lesions. The primary end point was a composite of time to death, MI, or repeat revascularization. A total of 562 patients underwent randomization. Among them, 60.0% underwent immediate PCI for non-infarct-related artery lesions and 40.0% were treated by a staged procedure during the same hospitalization. PCI was performed for non-infarct-related artery in 64.1% in the FFR-guided PCI group and 97.1% in the angiography-guided PCI group, and resulted in significantly fewer stent used in the FFR-guided PCI group (2.2 ± 1.1 vs. 2.5 ± 0.9, P < 0.001). At a median follow-up of 3.5 years (interquartile range: 2.7-4.1 years), the primary end point occurred in 18 patients of 284 patients in the FFR-guided PCI group and in 40 of 278 patients in the angiography-guided PCI group (7.4% vs. 19.7%; hazard ratio, 0.43; 95% confidence interval, 0.25-0.75; P = 0.003). The death occurred in five patients (2.1%) in the FFR-guided PCI group and in 16 patients (8.5%) in the angiography-guided PCI group; MI in seven (2.5%) and 21 (8.9%), respectively; and unplanned revascularization in 10 (4.3%) and 16 (9.0%), respectively.
Conclusion: In patients with acute MI and multivessel coronary artery disease, a strategy of selective PCI using FFR-guided decision-making was superior to a strategy of routine PCI based on angiographic diameter stenosis for treatment of non-infarct-related artery lesions regarding the risk of death, MI, or repeat revascularization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/eurheartj/ehac763 | DOI Listing |
Int J Cardiol
September 2025
Regional University Hospital Jean Minjoz, Besancon, France.
Background: The clinical benefit of using ICT for coronary stent optimization remains uncertain in randomized trials, in which a unique ICT was used in most cases.
Aim: To assess the clinical impact of intracoronary techniques (ICT) for stent optimization in high-risk patients.
Methods: The OPTI-XIENCE study is a prospective, observational, multicenter international study including high-risk patients undergoing coronary stenting, in whom any ICT was used for stent optimization at the operator's discretion.
JACC Asia
August 2025
Division of Cardiology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea; CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea. Electronic address:
Background: Following percutaneous coronary intervention (PCI), the "no-reflow phenomenon" is associated with a worse outcome. However, it remains unclear how to prevent and treat this phenomenon during PCI.
Objectives: This study aimed to evaluate the association between thrombogenicity profiles and "no-reflow phenomenon" during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI).
Catheter Cardiovasc Interv
September 2025
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Background: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) on ostial left circumflex (oLCx) is associated with a high rate of adverse events.
Aims: This study aims to compare drug-coated balloons (DCB) and DES in the treatment of oLCx lesions.
Methods: Consecutive patients undergoing DCB-PCI of de novo oLCx lesions (isolated or in the context of a distal left main bifurcation) in eight international centers from 2018 to 2023 were retrospectively enrolled and compared with a historical cohort of patients who received PCI with DES.
Circulation
September 2025
Department of Medicine, Stanford University, CA (D.J.M.).
Background: In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI). Whether the health status benefits of invasive management in ISCHEMIA were driven primarily by participants treated with CABG is unknown.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
First-generation drug-eluting stents (DES) with thick polymers may contribute to local vascular inflammation and late stent thrombosis. Thinner-strut DES, particularly those with biodegradable polymers and ultrathin struts, aim to reduce this risk by minimizing flow disturbance and vascular injury. Nonetheless, the long-term safety and efficacy of ultrathin biodegradable polymer sirolimus-eluting stents (BP-SES) compared to durable polymer everolimus-eluting stents (DP-EES) are still uncertain.
View Article and Find Full Text PDF